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8. Nutrition 
~ Intake of fat-soluble vitamins from supplements in adult patients 
with Cystic Fibrosis 
F. Hollander 1'2, N. de Roos 1 , J. Dopheide 1 , E Teding van Berkhout 2. 1Julius 
Center for Health Sciences and Primary Care, Department of Dietetics, 2 Cystic 
Fibrosis' Centre, Utrecht, The Netherlands' 
Introduction: CF patients have higher equirements for fat-soluble vitamins (vit A, 
D, E, and K) than healthy men and women. European CF guidelines recommend 
doctors to subscribe supplements of these vitamins. 
Aim of the study: To assess the intake of fat-soluble vitamins in adult CF patients 
registered at CF Center Utrecht. 
Subjects and Methods: We invited 111 out-clinic patients to take part in a 
telephone survey by a dietitian to assess type, frequency, dosage, duration and 
prescriber of the supplements. 
Results: Of the 93 respondents (age 28±8 years, 52 men), 75 (81%) used 
vitamin and/or mineral supplements. Fat-soluble vitamins as mono-supplements 
were exclusively used on prescription and had been used for >1 year. Thirty (40%) 
patients used vit A, 32 (43%) vit D, 51 (68%) vit E, and 23 (31%) vit K. 
Multivitamins were an important source of vitamins A, D, E and were used by 
36 patients. The mean (range) intake from mono+multivitamin supplements was 
492 (26 1212) gg/d of vit A, 5.9 (0.7 21) gg/d ofv i t  D, 99 (5 600) mg/d ofvit  E, 
and 63.7 (0.7 1500) gg/d ofv i t  K. 
Discussion: We did not collect data on vitamin intake from food and on serum 
values. Thus, no conclusion on the vitamin status of the patients could be drawn. 
Conclusion: Most patients used supplemental vitamins A, D, E and K, mainly on 
prescription. Recommended supplement use was met by only 12% of the patients 
for vit A, 27% for vit D, 55% for vit E and 45% for vit K. Moreover, even 
in supplement users the intake of vitamins was below the recommendations i  
the majority of patients. Thus, doctors and dieticians hould be more alert on 
vitamin supplementation. A yearly check of serum vitamin levels is recommended 
in CF patients. 
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Aim: Evaluation of the effect of Zn supplements in CF on number of pulmonary 
infections, antibiotic (AB) needs, caloric intake and growth. 
Method: A retrospective study of all CF patients who received a Zn supplement 
was performed. The number of infections, IV AB treatment, weight, height and 
caloric intake were collected uring the year before the Zn supplements and during 
the first year of supplementation. Caloric intake is expressed as 0/0 of recommended 
daily allowances for age + 30°/0 supplement for disease. Weight for height 0/0 is the 
0/0 of the ideal weight for height. The significance of the differences was calculated 
with a Wilcoxon-rank test. 
Result: Between Jan. 2000 and Dec. 2004, 21 patients (7 F) received 5 mg/kg 
Zn sulfate/day because of low serum Zn and poor appetite or impaired growth. 
The median age was 8.9 yr (1.1 26.5yr). The median serum Zn was 63.5 gg/dL 
(42 96) and increased significantly (p < 0.003) after one year 95.5 gg/dL (62 134). 
There was a trend towards decreased number of infections/yr with a median of 3 
infections before (1 7) vs. 2 (1 4) during supplementation (p < 0.03). The caloric 
intake improved from 93°/0 (73 143) to 108°/0 (73 150) of the advised caloric intake 
( RDA for age + 30°/0) (p < 0.02) as did the weight for height 0/0 from 90°/0 (71 
113) to 94°/0 (84 114) (<0.04). 
Conclusion: In this retrospective study there are arguments of beneficial clinical 
effects in selected CF patients. It should however, be sorted out with a double blind 
randomised controlled study. 
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~ Effect of feeding DHA on the fatty acid composition of intestinal 
mucosa in adults with CF 
M.T. Clandinin 1, N.E. Brown 1 , A.B.R. Thomson 1 , S.F.R Man 2, Y.K. Goh 1 , 
D.W Ma 3, J. Jumpsen 1 . 1Nutrition and Metabolism Research Group, Department 
of Medicine, University of Alberta, Edmonton, Alberta; 2Department of Medicine, 
University of British Columbia, Vancouver; 3Faculty of Medicine, University of 
Toronto, Toronto, Ontario, Canada 
The long-chain omega-3 fatty acid, Docosahexaenoic a id (DHA), is an important 
component of cell membrane phospholipids. A biochemical deficiency of DHA has 
been reported in blood and other tissues in CF patients, particularly in patients with 
the delta-F508 genotype. 
Aim: Adults with delta-F508 genotype CF were supplemented with DHA, for a six- 
week period. The bioavailability of this supplement was evaluated by comparing 
pre- and post-treatment fa ty acid profiles from intestinal mucosal biopsy samples. 
Methods: Five patients, aged 18 43, received 70rag DHA/kg body weight for 
six weeks. At baseline and at six weeks, a duodenal mucosal biopsy sample was 
obtained uring an endoscopic procedure. Lung function, dietary intake and blood 
chemistries were also analyzed. 
Results: One patient was dropped for non-compliance. An increase in DHA was 
observed in mucosal total phospholipids (TPL), phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE). 
20:4n-6 and 22:6n-3 (%w/w) in intestinal mucosa from CF subjects pre- and post-DHA 
supplementation 
20:4n-6 22:6n-3 
Pre- Post- Pre- Post- 
TPL 6.69 5.78 0.56 3.14 
PC 7.43 6.90 0.70 1.87* 
PE 14.63 15.19 1.75 5.58* 
* pre- vs post- p < 0.05 
Conclusions: Mucosal DHA levels of CF patients can be increased by supplement- 
ing with 70 mg DHA/kg/d. 
~ Vitamin D status in one regional adult Cystic Fibrosis centre 
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Cardiothoracic Centre Liverpool, UK 
Introduction: It is well known that sub-optimal levels of vitamin D may lead to 
bone disease and low bone mineral density in adult CF patients. Recent evidence 
suggests that optimal serum levels should be 30 60ng/ml, taking into account 
seasonal variation. All our patients are prescribed approximately 900 ius (22 gg/day) 
vitamin D, in combination with vitamin A. We wished to assess Vitamin D levels 
in our adult CF patients, to ensure that supplementation was adequate. 
Method: We measured 25 hydroxy Vitamin D (25-OHD) throughout 2004 in 
125 CF patients (mean age 25yrs [range 17 50], 8 pancreatic sufficient) and 
compared the values with the Northern Hemisphere reference ranges of 10 60 ng/ml 
(May to October) and 5 25 ng/ml (November to April). 
Results: Using these reference ranges, mean values in our patients fell within 
the accepted ranges (20ng/ml and 22ng/ml respectively). The average quarterly 
25-OHD levels in our patients were: Spring 21 ng/ml, Summer 19 ng/ml, Autumn 
23 ng/ml and Winter 20 ng/ml. 
The percentage of patients versus 25-OHD levels: 
25 O-HD (ng/ml) Mar-May Jun-Aug Sep-Nov Dec-Feb Total 
<10 4 2 2 5 14 
10 to 20 11 7 19 7 45 
20 to 30 5 6 9 5 27 
30 to 40 2 2 4 5 10 
40 to 50 0 1 2 0 2 
>50 2 0 0 0 2 
Only 17 patients (14%) had levels between 30 60ng/ml. 
Conclusion: Our patients did exhibit seasonal variations in 25-OHD levels. Al- 
though the majority appeared to have adequate l vels based on the accepted normal 
reference ranges, only 14% fell within the enhanced range recommended for 
CF patients. This suggests our current supplement policy may be inadequate, and 
this will be reviewed at our annual dietetic screen. 
